Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeuroSense Therapeutics Ltd. - Ordinary Shares (NQ:NRSN)

0.8099 +0.0599 (+7.99%)
Streaming Delayed Price Updated: 3:16 PM EDT, Apr 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeuroSense Therapeutics Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Wednesday's session: top gainers and losers ↗
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
The market is filled with gapping stocks in Friday's session. ↗
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads
NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads 
Via News Direct
Topics Regulatory Compliance
News headline image
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights ↗
NeuroSense expands PrimeC production, partners with a contract organization, and targets early Canadian entry amid a $100–150 million forecast and analyst Buy rating. 
Via Benzinga
News headline image
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday ↗
 
Via Benzinga
News headline image
NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement
Groundbreaking ALS Therapy Shows Remarkable Survival Benefits as NeuroSense Continues to Advance Toward Potential Partnership with Pharma Giant (NASDAQ: NRSN)* 
Via News Direct
News headline image
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
From Market News Alerts
Via Business Wire
News headline image
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
Bullish Wall Street Analyst Sees NeuroSense as a potential multibagger giving it a Buy Rating and $7.50 Price Target Representing a Significant Premium Over Current Prices; 
Via News Direct
Topics Regulatory Compliance
News headline image
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
From PESG Research
Via Business Wire
News headline image
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission ↗
NeuroSense Therapeutics schedules an FDA Type C meeting on Nov. 6 to finalize its Phase 3 trial design for PrimeC, a potential ALS treatment. 
Via Benzinga
News headline image
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market 
Via News Direct
News headline image
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug ↗
NeuroSense Therapeutics is in advanced talks with major pharmaceutical companies for a strategic partnership to develop and commercialize its ALS drug, PrimeC. The company expects to receive terms by... 
Via Benzinga
News headline image
NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024 ↗
NRSN stock results show that NeuroSense Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023 ↗
NRSN stock results show that NeuroSense Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
News headline image
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 ↗
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and... 
Via Benzinga
News headline image
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results. 
Via Benzinga
News headline image
US Stocks Higher; Private Payrolls Rise By 103,000 In November ↗
U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening Wednesday, the Dow traded up 0.21% to 36,200.86 while the NASDAQ rose 0.28%... 
Via Benzinga
Topics Stocks
News headline image
Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket ↗
Shares of SentinelOne, Inc. (NYSE: S) rose sharply in pre-market trading after the company reported stronger-than-expected results for its third quarter and raised its annual revenue outlook. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to dive into the biggest pre-market stock movers for Wednesday with a breakdown of all the latest news this morning! 
Via InvestorPlace
News headline image
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
News headline image
Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket ↗
Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted better-than-expected results for its third quarter and issued a stro 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning! 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
News headline image
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
Via ACCESSWIRE
News headline image
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeC ↗
Induced pluripotent stem cells (iPSCs) have emerged as a promising tool in the field of research and therapy for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). ALS is a... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.